Various approaches to cancer immunotherapy are commonly employed, including the utilization of immune checkpoint inhibitors that specifically target molecules involved in immune regulation, such as programmed cell death protein-1/ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4, as well as chimeric antigen receptor T cell therapy83. The gene discussed is PDCD1; the disease is cancer.